

**The British Association of
Urological Surgeons
Limited**

**Annual Report and Financial
Statements**

31 December 2023

Charity Registration Number 1127044

Company Limited by Guarantee

Registration Number 06054614 (England & Wales)

Contents

Reports

Reference and administrative details of the Society, its trustees and advisers	1
Trustees' report	2
Independent auditor's report	25

Financial statements

Statement of financial activities	29
Balance sheet	30
Statement of cash flows	31
Principal accounting policies	32
Notes to the financial statements	37

Reference and administrative details of the Society, its trustees and advisers

President	J Cresswell
Vice President	I Pearce
Honorary Treasurer	N Watkin (until 20 June 2023)
Honorary Treasurer	I Shergill (from 20 June 2023)
Honorary Treasurer Elect	I Shergill (until 20 June 2023)
Honorary Treasurer Elect	M S Ahmad (from 20 June 2023)
Honorary Secretary	I Pearce (until 20 June 2023)
Honorary Secretary	J Philip (from 20 June 2023)
Honorary Secretary Elect	J Philip (until 20 June 2023)
Honorary Secretary Elect	M Belal (from 20 June 2023)
Co-opted Trustees	G Singh S F Willis L Dodgshon M Lynch
Registered/Principal office	The Royal College of Surgeons England 38 - 43 Lincolns Inn Fields London WC2A 3PE
Charity registration number	1127044
Company registration number	06054614
Auditor	Buzzacott LLP 130 Wood Street London EC2V 6DL
Bankers	National Westminster Bank Plc Corporate Central Banking 5 -10 Great Tower Street London EC3P 3HX
Investment managers	CCLA Investment Management Limited Senator House 85 Queen Street London EC4V 4ET

The Trustees, who are also the directors of the charitable company for the purposes of company law, are pleased to present their annual report with the financial statements of The British Association of Urological Surgeons Limited (BAUS or The Association) for the year ended 31 December 2023.

This report has been prepared in accordance with Part 8 of the Charities Act 2011 and constitutes a directors' report for the purposes of company legislation.

The financial statements have been prepared in accordance with the accounting policies set out therein and comply with the charitable company's Articles of Association, applicable laws, Companies Act 2006 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) second edition, effective from accounting periods commencing 1 January 2020 or later.

Objectives and activities

Charitable objectives

The charitable objective for which the charity was established is:

To promote the highest standard in the practice of urology for the benefit of patients by fostering education, research and clinical excellence.

Urology deals with specific diseases and disorders of the male genitourinary and female urinary tract and urologists are medical and surgical specialists who treat men, women and children with kidney, bladder, prostate and urinary problems, covering benign and malignant disease. Urologists also care for men's sexual and reproductive health.

In order to meet the charitable objective, the Trustees of the Association have set an overall goal for BAUS to do everything in its powers to support education, research and clinical excellence in urology. In pursuance of this overall goal, the principal activity of the charity is the dissemination of information as it relates to the specialty.

In practice, the Association promotes and arranges scientific meetings and events covering every aspect of the practice of urology. The Association supports the education of urologists through courses, online learning, specialty focused meetings and a three-day annual scientific congress. The Association undertakes targeted audits to highlight and disseminate information about potential improvements in patient pathways and care. The charity also produces patient information leaflets relating to urological conditions and operations.

The Association's primary objectives in 2023 were to:

- ◆ focus on membership recruitment and retention, reviewing the range of membership benefits and pricing models.
- ◆ deliver a full calendar of events including educational courses, targeted sub-specialty meetings and a three-day annual scientific meeting.

Objectives and activities (continued)

Charitable objectives (continued)

- ◆ undertake an in-depth review of its education offering to ensure it continued to be relevant, accessible and valued by those who access it.
- ◆ continue to develop and promote best practice service models through audit and quality improvement and where appropriate by working with and giving input to other organisations such as GIRFT and NICE.
- ◆ engage in discussions and activities to better support the urological workforce including training guidance, recruitment and retention.
- ◆ develop a targeted strategy for communications to ensure they are fit for purpose and review current digital platforms to inform the development of a coordinated digital strategy.
- ◆ work on fully implementing the 10-Point Action Plan around widening participation with the aim of embedding the goals across the activities of the Association so that BAUS is an organisation that attracts membership from the widest group of clinicians and healthcare professionals and makes the specialty attractive to all.

Public benefit

The Trustees have taken the Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this Trustees' Report.

Benefits and beneficiaries

As stated above, in accordance with its charitable objectives, the Association strives to support education, research and clinical excellence in the specialty of urology. In so doing it seeks to improve the quality of medical care for the benefit of patients. The charity's ultimate beneficiaries are therefore patients, and benefits to patients are provided through advancing knowledge of, practice in and setting standards for, the specialty.

Urologists treat a broad spectrum of conditions across all age groups but, particularly with an ageing population, demand for care has been steadily increasing. Urologists and their teams treat three of the ten commonest cancers, prostate, kidney and bladder, as well as a wide range of benign conditions such as lower urinary tract symptoms (which affects 35-40% of men over 55 years of age), urinary tract stones and incontinence. BAUS provides ongoing professional and educational support to urologists to assist them in delivering high standards of care to their patients.

Achievements and performance

In 2023, the Association delivered ten face-to-face events (F2F). BAUS remains the key provider of education and professional development for all doctors working in the field of urological surgery.

Association membership was 2,339 in January 2023 rising to 2,409 in November 2023 (2,191 in 2022). At the present time, 80% (988 out of 1,239) of the substantive consultant urologists in the UK are BAUS members.

Events and activities

Annual Scientific Meeting

The Annual Scientific Meeting (ASM) was held in Birmingham on 19-21 June 2023. This is the largest event BAUS organises, and it was attended by 1,138 delegates (1,267 in 2022) with a further 245 virtual registrations (235 in 2022). In total 1,383 delegates registered for the meeting (1,502 in 2022).

Seven on site skills courses were offered, overall there were 140 places available on the skills courses and nine of the ten courses were sold out in advance with a total of 121 places booked and 95 attendees (134 attendees for ten courses in 2022). In 2023 five on site teaching courses were also offered with a total of 252 places available, 166 were booked and 137 attended. Nine virtual teaching courses were offered with a total of 1,357 views ranging from 91-304 per course (in 2022 22-84 for online courses with 677 views).

395 abstracts were submitted for consideration for inclusion in the Annual Scientific Meeting (379 in 2022), of which 116 (29%) were accepted for presentation at the meeting (164 in 2022, 43%). To increase the acceptance rate and facilitate engagement in the meeting more poster sessions will be included in the 2024 meeting.

There were 1,190 log ins to the online platform (1,320 in 2022). All delegates were sent an online review form after the meeting and 501 or 36% of active participants (523 / 35% in 2022) returned comments which were generally helpful and constructive and help to inform future programme planning. 98% of those commenting confirmed attendance at the BAUS meeting helped them to keep up to date in their practice:

It was my first time attending a conference and I enjoyed it and found it very informative!! Mr Belal's lecture in particular was very inspiring and something I will remember as I continue through my career (and life!).

Catching up online-allows you to see the entire programme at leisure and revisit the best bits.

Very important event in a practicing urologist's calendar

Achievements and performance (continued)

Events and activities (continued)

Annual Scientific Meeting (continued)

In 2023 BAUS offered seven sponsorship packages, but due to demand eight sponsorship packages were sold (five in 2022). In addition to these eight sponsors there were 51 exhibiting companies (46 in 2022), all available exhibition space was sold. Overall meeting sponsorship was 30% up on 2022.

Section meetings

A joint meeting of the BAUS Section of Endourology and the British Society of Urogenital Radiology was held on 14-15 September at the Harrogate Convention Centre attended by 200 urologists (188 delegates in 2022) and 177 radiologists. There were 38 exhibiting companies.

The Section of Oncology annual meeting was held on 13-14 November at the Bridgewater Hall in Manchester attended by 234 delegates (226 in 2022). There were 17 exhibiting companies.

94 (40%) of the delegates (68 /30% in 2022) returned feedback on the meeting and comments included the following:

Fantastic discussion of studies/trials emerging over the last year, along with discussion of some studies to look forward to or get involved in. Particularly liked the critique/interpretation of studies, and their potential for clinical practice.

Excellent session, great delivery and plenty of food for thought. I wonder if our unit should be moving towards fusion biopsy?

Good session, plenty of food for thought: I think we don't consider quality of life nearly enough when discussing radical surgery with our patients.

Made me see things from a different angle.

Very interesting, dispelled a few myths and presented some fascinating data.

Fantastic session, I wonder if we can recruit an Oncogeriatrician locally! This talk gave a fantastic insight into an often neglected area.

The Section of Female, Neurological and Urodynamic Urology (FNUU) organised a one-day meeting on 13 December at Hinxton Hall, Cambridge attended by 61 delegates and supported by seven exhibiting companies. 31 /56% of delegates returned feedback.

Achievements and performance (continued)

Events and activities (continued)

Educational courses

The Core Urology course runs annually and is targeted at surgical trainees who have just started, or are thinking about pursuing, higher specialist training in urology. In 2023 the course was run face-to-face over 4 days for the first time since January 2020, with 60 registrations (79 registrations for 3-day virtual course in January 2022). After five years in the role this was the last course to be organised by the current Course Director Miss Anna O'Riordan. 55 (92%) (51 (65%) in 2022)) of the delegates returned feedback:

An enormous thank you to Miss O'Riordan for being so kind, friendly, approachable and supportive all week. She really set the tone for a fantastic week of learning, fun and making new friends. She is an amazing leader and I would feel so lucky to have her as my TPD!! At a time when working as a junior doctor in the NHS feels completely bleak, this course was a ray of light that reminded me why I became a doctor in the first place. Thank you to all the speakers and everyone involved with the organisation of the course.

I think everything that a Core Trainee should know was covered very well..... The thing I most appreciated was Miss O'Riordan's talk at the end about 'work life balance' and about the podcasts she signposted us to. It was quite evident that this is a consultant who cares for her trainees in a holistic manner and not just strictly in a 'job plan' manner.

I am definitely happier for having attended the course..... This was also a great opportunity for networking and to socialise with our peers and meet others across the country who are likewise interested in urology. It gives you a great platform to know what other hospitals are like and know the nature and scope of work there.

An excellent course all round! Very inspiring speakers and excellent coverage of core Urology topics that will benefit my practice.

The general atmosphere was extremely welcoming and encouraging, which made this course unique from any other course I've attended previously.

In reply to a question about why they wanted a career in urology trainee responses included the following:

Great patient population, surgery is interesting, highly diverse colleagues, seniors in urology are the sort of people I'd like to work with / become.

The satisfaction associated with being able to make a huge difference to patients' quality of life with surgery and practical interventions, especially in an area of medicine where patients sometimes feel embarrassed about seeking help. The people - in my experience urologists are kind, good-natured, friendly surgeons who are passionate about their specialty and training. Urologists also work in fantastic multi-disciplinary teams both inside and outside of theatre. Urology is a specialty with endless innovation and new technology - over the course of a long career, there will always be new medications, new diagnostics, and new surgical techniques to keep things fresh and continue learning and developing.

Achievements and performance (continued)

Events and activities (continued)

Educational courses (continued)

The FRCS Urology examination is run by the Surgical Royal Colleges and success is a mandatory requirement for completion of specialist training which ultimately leads to entry on the GMC's Specialist Register, a requirement for appointment as a consultant. The examination is usually held twice each year and the BAUS FRCS (Urol) Revision Courses are held 4-6 weeks before each sitting and are run over five days.

In March 2023 the course was held in Birmingham with 60 participants, which was the maximum that could be accommodated (50 in London in 2022). The second revision course was at College Court, Leicester in September with 56 participants (58 in 2022).

In November the Section of Endourology ran the residential operative course at the University Hospital, Southampton. This intensive three-day course is limited to four delegates and is for senior trainees in their final year, post FRCS (Urol), who are aiming to be appointed to a Consultant post with a subspecialty interest in endourology. Each individual completing the course can apply for a £1,500 travelling scholarship to support a visit to an endourological centre of excellence. This was the first time the course had been run since 2019 and the trainees reported that the course was a fantastic opportunity for trainees to further their technical skills with the observations from an expert faculty.

The course felt representative of how I'd imagine the first couple of days as a consultant in a new centre would be. At once being both daunted by unfamiliarity and excited by subtle new challenges to familiar cases. It provided a rare but invaluable opportunity to operate 'away from home' and gain personalised feedback.

Immediately it was very impressive how organised the course was from the outset and it was clearly apparent a lot of time had gone into organising the two days. I believe it was safe to say we thoroughly enjoyed these two days and learnt new techniques we will take forward in our armamentarium.

During the course I really valued the opportunity to discuss challenging aspects of cases and to learn from experienced colleagues picking up tips and tricks from them and receiving personalised feedback throughout and after each case from multiple members of the faculty.

A benefit of the course was not only being directly supervised by experienced stone surgeons but also having the availability of the reps who were able to give advice particularly in relation to laser settings and new equipment coming to market. This course was of huge educational value to pick up operative tips but also make contact with like-minded colleagues and share experiences.

Skills courses

In 2022 BAUS began a collaboration with KARL STORZ to run a series of skills courses utilising the facilities at the KARL STORZ Training & Technology Centre (TTC), Slough. BAUS organises the faculty, determines the content and registers delegates and both parties collaborate to ensure there is good coordination and optimisation of access to skills training.

Achievements and performance (continued)

Events and activities (continued)

Skills courses (continued)

Two ureteroscopy courses were run in May and November with 16 and 21 delegates respectively (20 and 19 in 2022) and two endoscopic skills courses were run in May and December with 19 and 22 delegates respectively (20 for one course run in 2022). Course capacity was 20 delegates initially, later increased to 22.

Webinars

The SAS@BAUS project (see below), organised three webinars (five in 2022) which were aimed at doctors in the Staff and Associate Specialist (SAS) and Locally Employed Doctors (LED) grades, although numbers engaging with webinars has dropped off dramatically.

The Urolink Executive Committee continued to run a series of educational tutorial webinars. These take place between various UK training sites and link centres in central and east Africa. These tutorial presentations are trainee led, with senior moderation, and their focus is on discussing approaches to managing clinical scenarios in differing healthcare settings. Two webinars ran in 2023 (seven in 2022) and all webinars run to date remain on the website as an open resource.

Audit

There is a rolling programme of BAUS snapshot audits, with clear criteria for assessment of audit proposals based on safety, efficacy and accessibility criteria. The audits are developed by the Sections with the support of the Audit Steering Group (ASG) and BAUS Programme Manager. Audits are selected to address common problems where differences in practice are perceived and where changes in practice can benefit patients but do not exclude rarer conditions where, for example, unwarranted variation has been highlighted by the NHS Getting It Right First Time (GIRFT) programme. The audit programme aims to cover the breadth of urology, offering the potential for all urological units in the UK to participate. The metrics are patient-focused and the data collection and submission processes are designed to maximise case ascertainment. National data is reported but the main focus of the audits is to provide individual feedback to units for benchmarking and quality improvement.

The audits appear on the annual NHSE Quality Accounts List, which helps drive compliance and ensures integration into Trust governance processes for scrutiny of the results and generation of an action plan if required. There are case studies available to urologists from the audits which demonstrate how individual unit feedback to urology units has been a catalyst for driving changes in practice and service improvement. Local re-auditing is promoted through provision of audit templates and supporting documentation and guidance, thereby closing the audit loop.

Achievements and performance (continued)

Audit (continued)

REJOIN – (Emergency Ureteric Injury Management) Audit

Unit-level anonymised data was collected on management and outcomes of patients with ureteric injury between 1 February and 30 September 2022 inclusive. Data submission took place between October 2022 and February 2023. This audit aimed to improve understanding of the frequency of ureteric injuries and determine variations in practice and treatments in the UK. It also sought to identify whether trainees are getting enough exposure to this type of emergency and therefore also captured the number of units with zero cases during the audit period as this has an impact on training opportunities and can inform course development and provision. 187 complete datasets were captured from 78 units in the UK. A further 27 units reported no ureteric injuries during the audit period. Preliminary results were presented at the BAUS 2023 Annual Scientific Meeting and headline statements from the audit were made available to Members on the BAUS website. Abstracts were accepted for presentation at the European Association of Urology (EAU) and Society of Urodynamics, Female Pelvic Medicine and Urogenital Research (SUFU) in 2024. Further data analysis on complications and regional variation is ongoing.

C-PAT Audit – (National Audit of Patient Satisfaction with Cystectomy Pathway for Bladder Cancer) - PROM

Radical cystectomy with urinary diversion is a gold standard treatment for invasive or high-risk non muscle invasive bladder cancer (NMIBC). It is acknowledged that patient pathways are critically related to survival. However, little is known about patient perceptions of the quality of care they receive when undergoing cystectomy. This audit was a collaboration between BAUS and the patient charity Action Bladder Cancer UK (ABCUK) and was the first national audit focused entirely on patients' perceptions of the quality of care received on their cystectomy pathway using a validated PROM (C-PAT). It aimed to determine variations in pathways and treatments in the UK. All UK units performing cystectomy were identified and invited to participate in the audit, which launched in November 2022 and closed in June 2023. 33 of 49 centres participated, and 1714/2093 (81.8%) of patients who underwent cystectomy between 1 January 2021 to 31 July 2022 inclusive were alive at the snapshot study time point and eligible for inclusion. The questionnaire response rate was 1081/1714 (63%) across the participating centres.

Achievements and performance (continued)

Audit (continued)

Preliminary results were presented at the BAUS 2023 Annual Scientific Meeting and a national report and headline statements from the audit were uploaded onto the BAUS website after the meeting. All participating units were emailed individual unit reports, benchmarked against the national data. A paper is being finalised for submission to the journal European Urology.

The C-PAT PROM and the MITRE snapshot audit undertaken in 2022 are components of a longer-term Section of Oncology project over 3-4 years to develop the evidence base for a nationally funded bladder cancer audit. BAUS is working with patient groups and other professional organisations to campaign for a national bladder cancer audit.

Nephrostomy Audit

The nephrostomy audit was launched at the Section of Endourology Annual Meeting in September 2023. Sepsis due to an infected obstructed kidney is a serious urological emergency that needs prompt and appropriate management. Although there is consensus on diagnosis and immediate resuscitation of the patient, provision for further management of draining the infected obstructed kidney is not uniform across the different hospitals depending on availability of on-call interventional radiology service. The upcoming centralisation of vascular services will impact further on appropriate and timely access to interventional radiology for management of patients requiring nephrostomy insertion. The Section developed a Consensus Statement, in consultation with BAUS members and consultant interventional radiologists, to create a comprehensive management pathway and series of statements to aid clinicians. The audit will collect retrospective unit level data on all patients undergoing primary nephrostomy in an obstructed infected kidney as an emergency in October and November 2023. Data submission will take place in February 2024.

Three future audits were approved by the Audit Steering Group for development and piloting by the Section of Oncology, the Section of Andrology and Urogenital Surgery and the Section of Trainees.

The Impact of Diagnostic Ureteroscopy on Radical Nephroureterectomy and Compliance with Standard Care (I-DUNC) Audit

Unit-level anonymised data will be collected on all patients undergoing radical nephroureterectomy (RNU) for suspected urothelial cancer (UTUC) between 1 July 2022 and 31 July 2023, and subsequent follow-up data including the number of patients who had post-RNU bladder mitomycin-C (MMC) and the number of patients receiving adjuvant chemotherapy for T2 or higher disease. Data submission will take place between 1 April and 30 April 2024 inclusive. UTUC requires timely and accurate diagnosis and treatment. RNU is the surgical standard of care for patients with suspected UTUC but there is currently no consensus on the best diagnostic evaluation strategy for these patients.

The aims of the audit are to assess national practices for diagnostic evaluation of patients with suspected UTUC and the impact of diagnostic ureteroscopy on the outcomes of RNU and evaluate national compliance with standard-of-care practices such as MMC administration and adjuvant chemotherapy in T2 or higher disease.

Achievements and performance (continued)

Audit (continued)

Penile Fracture (SNAP) Audit

Unit-level anonymised data will be collected on all patients undergoing a surgical repair for a suspected or confirmed penile fracture between 1 April 2023 and 31 March 2024. Data submission will take place from 1 March to 31 March 2025 inclusive.

Environmental Lessons Learned and Applied to the Bladder Cancer Care Pathway (ELLA) Audit

Anthropogenic climate change is a global emergency and healthcare is responsible for 5% of global greenhouse gas emissions. The NHS has a net zero greenhouse gas emissions target of 2045. Achieving this goal will involve adaptation and innovation throughout healthcare. The GIRFT Programme has developed guidance for the bladder cancer pathway, aimed to show healthcare teams how they can quickly realise significant greenhouse gas emission reductions. The audit aims to assess and identify variations in practice related to the most important GIRFT decarbonisation recommendations for the bladder cancer care pathway across the UK and estimate hospital level excess greenhouse gas emissions compared to optimal 'low carbon' practice. Data will be collected on specific points across the bladder cancer care pathway for 20 consecutive patients from 1 August 2024. Data submission will take place between 1 September 2024 and 31 October 2024.

National Consultant Information Programme (NCIP) - Urology Vanguard

BAUS continued its partnership with NCIP to provide urologists with access to routinely collected data in a format which gives them high quality supporting information for appraisal and professional development and enables local and national benchmarking to help improve quality and patient safety. All consultant urologists in England now have access to their individual and unit level data in the NCIP portal. There are 35 urology dashboards in the tool and urologists also have access to the stress incontinence and paediatric urology dashboards in the Gynaecology and Paediatric Surgery portfolio if they undertake these procedures. A group of urologists selected by BAUS worked with NCIP content developers to refine the complications metric for uro-oncological procedures in NCIP and this is now generating more meaningful data.

A new and improved version of the NCIP portal was launched in October 2023, BAUS supported the re-launch by hosting a webinar aimed at Trust Clinical Leads to introduce them to the new functionality and co-hosting a GIRFT NCIP webinar for all urologists showcasing the new look and new features. The recorded webinars are accessible through the BAUS, GIRFT and NHS Futures websites. BAUS contributed to joint messaging and communications, promotion of NCIP at BAUS and other appropriate urological meetings and engagement with Clinical Leads. BAUS continued to provide a user feedback form on its website and urology-specific podcasts and webinars.

BAUS also continued work with GIRFT on the co-development and publication of coder and clinician guidance for a range of urological procedures to improve the conformity of coding nationally, which is available on the BAUS and GIRFT websites.

Achievements and performance (continued)

Audit (continued)

National Consultant Information Programme (NCIP) - Urology Vanguard (continued)

NCIP only applies to England but BAUS is supporting its members in the devolved nations by sharing learning from the Association's collaboration with NCIP that can be applied to data collection projects in Wales, Scotland and Northern Ireland.

Workforce

BAUS has undertaken annual workforce surveys since 2009 and uses the information to contribute to discussions on workforce planning and identify longitudinal workload trends. The report on the 2022 data was published in June 2023. In addition to the BAUS census data, the report drew on information from the General Medical Council (GMC), NHS Digital, the Joint Committee on Surgical Training and the Specialist Advisory Committee (SAC) in Urology. The 2023 report included regional data to show the number of urologists per head of population demonstrating a marked variation across the country.

Essay and Audit Competitions

BAUS aims to raise the profile of the specialty amongst medical students, to encourage junior doctors to consider a career in urology and to inspire the next generation of urologists to engage with the Association. To this end BAUS runs an essay competition for medical students and an audit or quality improvement project competition for Foundation Year and Core Trainees (FY & CTs). In 2023 17 submissions were received for the essay competition (32 in 2022); the title set was "What steps can be taken in Urology to recover from the COVID pandemic? How do we address health inequalities exposed by the pandemic? How do we promote good Urological health?". In 2023, 17 submissions were received for the audit competition (18 in 2022). The national winners were invited to attend the Annual Scientific Meeting and were invited to present their work in the Medical Student session and Core Trainees session at the meeting. Prizes and certificates were presented to the winners.

Widening Participation

In July 2021 BAUS published its 10-point action plan around widening participation. The aim is to embed the goals across the activities of the Association so that BAUS is an organisation that attracts membership from the widest group of clinicians and healthcare professionals and makes the specialty attractive to all.

The Equality, Diversity and Inclusion (EDI) working group, which includes two Trustees and reports directly to the Board, held several meetings in 2023 and progressed a number of workstreams. In 2022 a data collection exercise aimed at helping BAUS to understand the diversity of BAUS was piloted with all those holding leadership roles within BAUS. Current data shows that 69% of BAUS Committee members are male and 31% are female, the GMC Specialist Register for Urology shows that 86% of urologists are male and 14% female. There is an insufficient volume of data to support further reporting at this time.

Achievements and performance (continued)

Other activities (continued)

In all meetings and conferences there was a drive to ensure that the faculty invited to participate in sessions represented a diverse and inclusive range of BAUS members. At the annual meeting there were a number of EDI themed sessions:

In its ten-point action plan BAUS had committed to developing a code of conduct for meeting chairs and panellists to follow in order to avoid inappropriate comments and bystander apathy

and this was piloted at the Section of Oncology meeting in November 2023 and will be rolled out to all meetings in 2024.

Widening Participation (continued)

Point 6 of the Plan was to prime the pipeline for leadership into BAUS roles. During 2023 the working group developed plans for a shadowing scheme to allow members, at any stage of their careers, to gain a deeper understanding of the functions of BAUS's committees. This will be piloted in 2024.

BAUS Digital and Communications Strategy

The BAUS Digital Working Group, including representation from across the BAUS membership, a Trustee and an external digital consultant (whose time has been provided at no cost to the organisation), held its first meeting in January 2023. The specific remit of the group was to assess the potential and make recommendations for a digital tool which would support the BAUS communication strategy to better meet the needs of the membership. The Working Group quickly established the potential for a web app, and a subsequent proposal for the development of the tool, including a re-fresh of the current website, was approved by Trustees in March.

During the second half of 2023 the Working Group, supported by Light Media (the external agency managing the BAUS website) worked to define the scope and functionality of the web app. Following final stages of technical development the web app will be launched at the 2024 BAUS Annual Meeting. In parallel, the BAUS website has undergone a make-over in terms of design and overall functionality and will be launched alongside the web app. The work on the website has been supported by both the Working Group and by the surgical web editor Nigel Bullock.

Work on the area of BAUS communications in general concluded a number of recommendations, one of which was to reduce the overall amount of communication regarding BAUS business that was emailed to the membership each week. As a result, a BAUS Weekly Newsletter is now in place which summarises a number of individual communications into a single weekly round-up. The Newsletter will be further developed as a more interactive and personalised offering within the web app.

Urolink

Urolink works with a number of centres, mainly in East and Central Africa, to support the development of urological services.

Achievements and performance (continued)

Other activities (continued)

Urolink (continued)

There were a number of visits and workshops undertaken in 2023 including a reconstructive workshop in Hawassa in February, a paediatric surgical camp in Malawi in March and a UroGynae scoping visit to Malawi in April. In April 2023 Urolink Committee member Nick Campain undertook a visit to Ndola in the Copperbelt region of Northern Zambia. Urolink has a longstanding link with University Teaching Hospital (UTH) in Lusaka, Zambia. Dr Simon Mukosai and Dr Mumba Chalwe previously completed their urological training at UTH and have subsequently set up a urology department and training programme at Ndola teaching hospital. This was a scoping visit to meet the team and hospital management, assess caseload and facilities, deliver some teaching activities and understand the local infrastructure with a view to establishing a longer-term link. In May Maxine Tran led a scoping visit to four centres in Hanoi, Vietnam. Although technologically more advanced than many centres in sub-Saharan Africa, there are many differences in care provision and methods of training that could be helped by Urolink. Urolink supported the 14th Lester Eshelman Urological Workshop Tanzania in November with more than 70 delegates and excellent feedback. Urolink funded the conference expenses and provided five faculty members. In December 2023 the Chair of Urolink attended the College of Surgeons of East, Central and Southern Africa (COSECSA) examinations in Ethiopia.

Detailed reports on all activities are included on the Urolink pages on the BAUS website.

Financial review

Financial results of activities and events

The Association's finances are stable, in 2023 there was an operating surplus of £210,886 (2022 – surplus of £15,636), against a budgeted deficit of £160,368.

The direct surplus from the 2023 Annual Scientific Meeting (ASM) was £237,588 (2022 - £137,718), which was the best surplus since 2016. Income from the 2023 meeting was £909,802 (2022 meeting income £709,945). Expenditure on the meeting was £672,214 (2022 meeting expenditure - £572,227). The increase in expenditure on the meeting was attributable to a number of factors including upgrades to the lunchtime catering in the exhibition hall, provision of a creche and increased audio visual and technical costs associated with offering the meeting with a hybrid format.

BAUS returned to a full programme of educational events in 2023, these activities generated a direct surplus of £32,247 in 2023 as opposed to £48,586 in 2022. The Section of Oncology and Section of Endourology annual meetings generated surpluses of £33,923 and £43,499 respectively (£26,857 and £34,679 in 2022).

Six industry sponsored webinars (BAUS sponsored Innovations in Urology programme) ran in 2023 as opposed to one in 2022 generating a surplus of £59,083.

Financial review (continued)

Financial results of activities and events (continued)

In 2023 subscriptions generated £580,418 (2022 - £565,185) which amounted to 27% of the Association's income in 2023 compared to 30% in 2022 and 46% in 2021.

Reserves policy and financial position

The "free reserves" of BAUS at 31 December 2023, calculated as the total general funds of the Association less the value of fixed assets, amounted to £3,140,275 (2022 - £2,773,967).

Usually, the Annual Scientific Meeting (ASM) generates about 30-40% of BAUS' income, in 2023 the ASM accounted for 43% (38% in 2022 and 17% in 2021) and the meeting accounts for 36% of BAUS's expenditure, with contracts for the meeting venues agreed several years in advance. BAUS has always been aware that it is exposed to significant financial risks in organising events, the costs associated with running events have significantly increased and it is not possible to pass all these costs on to delegates. The Trustees regard it as prudent to retain sufficient reserves to cover the costs of an Annual Scientific Meeting, plus any future contractual commitments, including pension provisions and, in addition, covering about six months of operational expenditure under normal circumstances. On this basis, free reserves of at least £2,500,000 should be maintained.

Even as BAUS' range of activities has continued to expand the staffing levels have remained pretty constant over a number of years. In 2023 BAUS carried some staff shortages for most of the year and it anticipates investment in staff recruitment and consultancy services to support the strategic priorities and future proof the organisation.

The Trustees are confident that the levels of reserves that BAUS holds, which are readily accessible, is such that BAUS will be able to continue to operate effectively.

Investments policy

The Trustees are empowered to invest any money that the Association does not immediately need in such a manner as they may determine.

At 31 December 2023 the Trustees held £2,348,906 (£2,151,228 in 2022) of the Association's free reserves in the COIF Charity Funds Scheme managed by CCLA Investment Management. Of this £1,000 (£1,000 in 2022) was held as cash by the investment managers and the remainder was invested. The balance of free reserves, £791,369 (£621,739 in 2022) was held as current assets, principally cash in interest bearing bank accounts.

The Trustees take professional advice from, and are responsible for managing the relationship with, the Association's investment manager, CCLA. The Association's investment strategy is to seek a long-term total return comprising growth in capital and income with a medium level of investment risk. The Trustees have delegated certain discretionary powers of investment to CCLA but can approve changes to the overall investment strategy (for example where an emphasis may be put on capital growth) meaning a slight increase in the relative risk exposure. The Trustees will keep the performance of the investment managers under review and will review their investment strategy on an annual basis.

Financial review (continued)

Investments policy (continued)

Performance of the COIF Charities Investment Fund is measured against the bespoke benchmark used by the Fund and by the ARC Steady Growth Charity Index which is used to measure peer group performance.

During the year, investment values rose 9.2% compared to the market value at the end of the previous year (11.6% fall in 2022) and generated investment income at an average rate of 3.0% (2.6% in 2022). During the year the Association's cash balances generated income at an average rate of 1.66% (0.38% in 2022). This reflected the prevailing economic climate and the trustees are satisfied with the performance.

Governance, structure and management

Status and History

The British Association of Urological Surgeons Limited is a registered charity, and a company limited by guarantee, not having a share capital. Every member undertakes to contribute an amount not exceeding £1 to the assets of the charity in the event of the charity being wound-up during the period of membership, or within one year thereafter.

BAUS originally came into existence as an unincorporated association that was founded in 1945 and has always functioned as a charity. The current corporate entity was incorporated on 16 January 2007 and became a registered charity on 4 December 2010.

The Association is governed by the regulations set down in its company Articles of Association, which were reviewed and updated in 2020, formally adopted at the Annual General Meeting on 29 September 2020 and subsequently filed with Companies House and the Charity Commission.

Organisational structure

The Trustees of BAUS have legal and fiduciary responsibility for the Association. The Trustees are the Officers of the Association (the President, Vice President, Honorary Secretary, Honorary Secretary Elect, Honorary Treasurer and Honorary Treasurer Elect) and up to four co-opted Trustees.

The following key senior members of staff are responsible for the day-to-day management of the charity:

E A Bishop Chief Executive and Company Secretary

P Hagan Deputy Chief Executive

The Association currently employs three part-time and five full time members of staff.

Governance, structure and management (continued)

Organisational structure (continued)

The following members have served on the Council since 1 January 2023:

Elected Regional Representatives

R Barod	(2021-2024)	
D Burke	(2021-2023)	(to 20 June 2023)
B Duggan	(2021-2024)	
V During	(2021-2024)	
G Durkan	(2019-2024)	
S Garnett	(2020-2025)	
W Green	(2021-2024)	
M Johnson	(2020-2023)	(to 20 June 2023)
G Kanda Swamy	(2019-2024)	
L Kerr	(2022-2025)	
R Lockyer	(2021-2024)	
M Lynch	(2019-2024)	
V Modgil	(2023-2026)	(from 20 June 2023)
R Morrison	(2021-2025)	
A Nambiar	(2023-2026)	(from 20 June 2023)
B Patel	(2019-2024)	
N Shah	(2019-2024)	
H Simpson	(2021-2024)	

Governance, structure and management (continued)

Organisational structure (continued)

Ex-officio Council Members

M Lucky	(2022-2023)	Chair, Section of Andrology and Genito-Urethral Surgery
S Sriprasad	(2022-2023)	Chair, Section of Endourology
M Belal	(2022-2023)	Chair, Section of Female, Neurological and Urodynamic Urology
J Aning	(2023-2024)	Chair, Section of Oncology
S Nalagatla	(2023-2024)	Chair, Section of Trainees
M Garthwaite	(2023-)	Chair, The Urology Foundation (TUF)
A McNeill	(2021-)	Chair, Executive Committee BJU International
N Soomro	(2023-2027)	Council RCS England
S Hillery	(2022-)	President, British Association of Urological Nurses Representative (<i>invited non-voting</i>)
A Dickinson	(2019-2023)	Chair, Audit Steering Group
S Natalwala	(2021-2023)	SAS Members Representative
C Moore	(2021- 2023)	Surgical Specialty Lead for Research

Key management

The Trustees consider that they, together with the Chief Executive and Deputy Chief Executive, comprise the key management of the charity in charge of directing and controlling, running and operating the charity on a day-to-day basis.

None of the Trustees receives remuneration in connection with their duties as trustees. The employing trust of the BAUS President is reimbursed for two sessions per week and there is an option to reimburse the Vice President and Honorary Secretary's trusts for one session respectively per week to ensure they have sufficient protected time to undertake the roles. Remuneration for all BAUS staff (including the Chief Executive and Deputy Chief Executive) is agreed by the Trustees who normally receive an annual confidential salary review report from an independent HR Consultant. The report contains salary review statistics and benchmarking of all job descriptions.

Method of recruitment, appointment, election, induction and training of Trustees

Recruitment

Details of vacancies for Officer posts are circulated to voting members of the Association. Candidates, who must be voting members in good standing, are proposed and seconded by appropriate sponsors, also voting members in good standing, and nomination forms are submitted to the Secretariat by a given date. Candidates are required to provide a written statement in support of their application, the details of which are circulated to the members who are the electorate. The election process is conducted in accordance with the Rules of the Association.

Governance, structure and management (continued)

Method of recruitment, appointment, election, induction and training of Trustees
(continued)

Appointment and election

The following procedural details apply to the Officers:

The Officers of the Council comprise the President, Vice President, Honorary Treasurer, Honorary Treasurer Elect, Honorary Secretary and the Honorary Secretary Elect, all of whom have their elections confirmed at the Annual General Meeting.

The President holds office for two years from the time of the Annual General Meeting. The Vice President holds office for two years thereafter becoming President.

The Honorary Secretary and Honorary Treasurer hold office for two years from the time of the Annual General Meeting. The Honorary Secretary Elect and the Honorary Treasurer Elect hold office for two years thereafter becoming Secretary/Treasurer.

Trustees can co-opt up to four members, one of the co-opted Trustees was appointed from among the elected Regional Council members (following interview) and two more members were appointed as co-opted Trustees after a recruitment process in 2020. Following changes to the Articles of Association in 2020, a lay Trustee was appointed.

Induction and training

To be eligible for election as a Trustee an individual must be a voting member of the Association, and therefore all of those elected will have a degree of familiarity with the workings of the Association which are set out in full on the BAUS website. However, mindful of the importance of Trustee induction and training, the Association has developed an induction pack for new Trustees and this is given to all Trustees on election and appointment.

The induction pack includes 'The Essential Trustee – what you need to know' published by the Charity Commission, the Trustees' Report and financial statements for the previous year, minutes of Trustee and Council meetings for the 12-month period before the newly elected/appointed Trustees formally begin their period of office, the Association's risk register and other general information – including the dates and times of future Trustees' meetings. In 2023 induction meetings were held by the President, Vice President and senior staff with the newly elected Trustees. Additional training is provided by the charity for Trustees on an on-going basis as the need arises.

Risk and corporate governance matters

The Trustees of the Association have been tasked with risk management and corporate governance matters. The Trustees and the Council generally take a low-risk approach to the management of the Association and they seek to minimise all risk exposure through good governance by maintaining adequate and appropriate systems and procedures throughout the operations of the Association.

Governance, structure and management (continued)

Risk and corporate governance matters (continued)

The Association maintains a comprehensive risk register which is reviewed regularly by the Trustees. The highest risks identified in the 2023 review remain loss of key staff and loss of income and dependency on a limited number of income sources.

The development of a strategic plan allows for a comprehensive review of work programmes and priorities which includes a review of staff resources against workplans to ensure resilience, sustainable performance and effective risk management.

The Trustees are satisfied that appropriate processes and policies are in place to manage the major risks identified to an acceptable level.

Sub-Committees

Under the Association's Rules the Trustees may establish (and disestablish) such committees as they think fit and delegate any of their functions to committees of BAUS. One member of every committee must be a Trustee. The main committees of BAUS are as follows:

The UROLINK Committee

The UROLINK Committee usually meets virtually at least twice a year, and is responsible for the organisation, financial administration and running of UROLINK. UROLINK aims to encourage and support the establishment of links with individual departments and organisations in low-income countries and to facilitate professional visits to work with colleagues.

BJU International and The Urology Foundation (TUF) continue to support activities at designated centres in Lusaka and Hawassa respectively and funds donated are held in a reserve account. Progress reports are submitted to BJU International and TUF on a regular basis.

Education Committee

During 2023 an education operational committee comprising the three Educational Leads (for Specialty Trainees, FY/CTs and Medical Students), two BSoT Education representatives and an SAS/LED representative maintained oversight of the delivery of BAUS education events and courses as well as some development work. The structure and role of the Education committee will be informed in the context of the Association's strategic development process including an Education Review.

Governance, structure and management (continued)

Sub-Committees (continued)

Audit Steering Group

The remit of the ASG is to provide leadership and strategic oversight across all data and audit activity within BAUS.

In 2023, work continued to be focussed on:

- ◆ Relationship building, networking and partnering with national programmes for quality improvement; Getting it Right First Time (GIRFT), the National Consultant Information Programme (NCIP), and UK-wide urology patient charities;
- ◆ Support for development and delivery of new audits; and
- ◆ Engagement with the membership, promotion of audit as a tool for quality improvement and dissemination of best practice.

Sub-Specialty Sections

BAUS has four sub-specialty sections:

- ◆ BAUS Section of Oncology formed in 1998;
- ◆ BAUS Section of Endourology formed in 2002;
- ◆ BAUS Section of Female, Neurological and Urodynamic Urology formed in 2002; and
- ◆ BAUS Section of Andrology and Genito-Urethral Surgery formed in 2003;

These sections aim to improve standards and quality of practice, within their sub-specialties, by promoting training, research and development. Members of the Association can join up to three sections which are relevant to their particular areas of practice.

In addition to the sub-specialty Sections, in 2018 a BAUS Section of Trainees was formed (BSoT). All trainee members of BAUS are automatically members of BSoT.

In 2023 BAUS agreed to establish a new Section of SAS & Trust Urologists (SSTU), replacing the SAS@BAUS working group which had been set up to offer career support and guidance for BAUS members who are Specialty and Associate Specialist (SAS) doctors or Locally Employed Doctors (LEDs). Plans to establish the Section were reported at the Annual General Meeting and recruitment to membership began in the second half of the year. Elections to the executive committee were held before the year end so that the Section could begin work in 2024.

Each section is administered by its own Executive Committee which is elected from within the sections' membership. The surgeons who make up the Executive Committees of each of the sections give their time voluntarily to these activities. The section chairs are ex-officio members of BAUS Council.

Plans for future periods

Future strategy

The 2023-26 Strategic plan was presented to BAUS Council in January 2023, the plan informs and guides BAUS' activities for the coming years.

Membership

OUTCOME– That those delivering urological care become active members of BAUS at all stages of their careers so enabling BAUS to be relevant, representative, inclusive and effective.

In 2024 BAUS will review member communications and promotional opportunities to support recruitment and retention.

Education

OUTCOME – That members are supported to access lifelong learning in urology.

Education has been described as the 'heartbeat' of BAUS; it is the Association's core business. In 2024 BAUS will:

- ◆ deliver a full calendar of events including educational courses, targeted sub-specialty meetings and a three-day annual scientific meeting.
- ◆ establish a new structure to guide, evaluate and optimise BAUS's educational offer.

Provision of Urological Care

OUTCOME – BAUS' professional expertise is harnessed to contribute to equitable access to urological care for all patients in the UK.

BAUS will continue to develop and promote best practice service models through audit and quality improvement and where appropriate by working with and giving input to other organisations such as GiRFT and NICE.

Engagement in discussions and activities to better support the urological workforce including training guidance, recruitment and retention.

In addition to the core themes mentioned above, BAUS will develop a targeted strategy for communications to ensure they are fit for purpose including an update of the website and the launch of a progressive web app.

Work on fully implementing the 10-Point Action Plan around widening participation will continue. The aim is to embed the goals across the activities of the Association so that BAUS is an organisation that attracts membership from the widest group of clinicians and healthcare professionals and makes the specialty attractive to all.

Statement of Trustees' responsibilities

The Trustees (who are also directors of The British Association of Urological Surgeons Limited for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the income and expenditure of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:

- ◆ select suitable accounting policies and then apply them consistently;
- ◆ observe the methods and principles in Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland (FRS 102);
- ◆ make judgements and estimates that are reasonable and prudent;
- ◆ state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- ◆ prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

Each of the Trustees confirms that:

- ◆ so far as the Trustee is aware, there is no relevant audit information of which the charitable company's auditor is unaware; and
- ◆ the Trustee has taken all the steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

Statement of Trustees' responsibilities *(continued)*

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

Approved by the Trustees and signed on their behalf by:

A handwritten signature in black ink, appearing to read 'J Cresswell'.

J Cresswell

Approved by the Trustees on: 13 May 2024

Independent auditor's report to the members of The British Association of Urological Surgeons Limited

Opinion

We have audited the financial statements of The British Association of Urological Surgeons Limited (the 'charitable company') for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, and statement of cash flows, the principal accounting policies and the notes to the financial statements. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- ◆ give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its income and expenditure for the year then ended;
- ◆ have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- ◆ have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report and financial statements, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- ◆ the information given in the trustees' report, which is also a directors' report for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- ◆ the trustees' report, which is also the directors' report for the purposes of company law, has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- ◆ adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- ◆ the financial statements are not in agreement with the accounting records and returns; or
- ◆ certain disclosures of trustees' remuneration specified by law are not made; or
- ◆ we have not received all the information and explanations we require for our audit; or
- ◆ the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- ◆ the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations; and
- ◆ we obtained an understanding of the legal and regulatory frameworks that are applicable to the charity and determined that the most significant frameworks which are directly relevant to specific assertions in the financial statements are those that relate to the reporting framework (Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Companies Act 2006).

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- ◆ making enquiries of management as to their knowledge of actual, suspected and alleged fraud; and

Auditor's responsibilities for the audit of the financial statements (continued)

- ◆ considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- ◆ performed analytical procedures to identify any unusual or unexpected relationships;
- ◆ tested journal entries to identify unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- ◆ reading the minutes of meetings of those charged with governance; and
- ◆ enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



20 May 2024

Edward Finch (Senior Statutory Auditor)
For and on behalf of Buzzacott LLP, Statutory Auditor
130 Wood Street
London
EC2V 6DL

Statement of financial activities Year to 31 December 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	2022 £
Income and expenditure							
Income:							
Investment income	1	81,108	—	81,108	67,549	—	67,549
Income from charitable activities							
. Dissemination of information	2	2,105,268	394	2,105,662	1,789,599	7,000	1,796,599
Total income		2,186,376	394	2,186,770	1,857,148	7,000	1,864,148
Expenditure							
Expenditure on charitable activities							
. Dissemination of information	3	1,969,167	6,737	1,975,904	1,829,476	19,036	1,848,512
Total expenditure		1,969,167	6,737	1,975,904	1,829,476	19,036	1,848,512
Net income (expenditure) before gains on investments		217,209	(6,343)	210,886	27,672	(12,036)	15,636
Net gains (losses) on investments	11	197,678	—	197,678	(283,064)	—	(283,064)
Net income (expenditure)		414,887	(6,343)	408,544	(255,392)	(12,036)	(267,428)
Transfer between funds	14	—	—	—	—	—	—
Net movement in funds		414,887	(6,343)	408,544	(255,392)	(12,036)	(267,428)
Reconciliation of funds:							
Fund balances brought forward at 1 January 2023		3,155,255	30,485	3,185,740	3,410,647	42,521	3,453,168
Fund balances carried forward							
at 31 December 2023		3,570,142	24,142	3,594,284	3,155,255	30,485	3,185,740

All of the charity's activities derived from continuing operations during the current financial period.

All recognised gains or losses are included in the above statement of financial activities.

Balance sheet 31 December 2023

	Notes	2023 £	2023 £	2022 £	2022 £
Fixed assets					
Intangible fixed assets	9		38,400		—
Tangible fixed assets	10		7,244		9,204
Investments	11		2,348,906		2,151,228
			2,394,550		2,160,432
Current assets					
Stocks		4,147		5,126	
Debtors	12	870,744		796,682	
Cash at bank and in hand		1,131,146		848,618	
		2,006,037		1,650,426	
Liabilities:					
Creditors: amounts falling due within one year	13	(806,303)		(625,118)	
Net current assets			1,199,734		1,025,308
Total net assets			3,594,284		3,185,740
The funds of the charity:	14				
Restricted funds					
. UROLINK funds			24,142		30,485
Designated funds					
. Endourology funds			345,796		315,031
. BSoT fund			38,427		57,053
Unrestricted funds:					
. General funds			3,185,919		2,783,171
			3,594,284		3,185,740

Approved by the Trustees
and signed on their behalf by:



President



Honorary Treasurer

Approved on: 13 May 2024

The British Association of Urological Surgeons Limited
Registered Company Number: 06054614 (England and Wales)

Statement of cash flows 31 December 2023

	Notes	2023 £	2022 £
Cash inflow from operating activities:			
Net cash provided by operating activities	A	241,482	28,524
Cash inflow from investing activities:			
Dividends and interest from investments		81,108	67,549
Purchase of intangible fixed assets		(38,400)	—
Purchase of tangible fixed assets		(1,662)	(1,121)
Net cash provided by investing activities		41,046	66,428
Change in cash and cash equivalents in the year		282,528	94,952
Cash and cash equivalents at 1 January 2023	B	848,618	753,666
Cash and cash equivalents at 31 December 2023	B	1,131,146	848,618

Notes to the cash flow statement for the year to 31 December 2023.

A Reconciliation of net movement in funds to net cash flow from operating activities

	2023 £	2022 £
Net movement in funds (as per the statement of financial activities)	408,544	(267,428)
Adjustments for:		
Depreciation charge	3,622	3,726
Amortisation charge	—	9,360
(Gains)/Losses on investments	(197,678)	283,064
Dividends and interest from investments	(81,108)	(67,549)
Decrease in stocks	979	1,361
(Increase) in debtors	(74,062)	(91,805)
Increase in creditors	181,185	157,795
Net cash provided by operating activities	241,482	28,524

B Analysis of cash and cash equivalents

	2023 £	2022 £
Cash at bank and in hand	1,130,146	847,618
Cash held by investment managers	1,000	1,000
Total cash and cash equivalents	1,131,146	848,618

Principal accounting policies 31 December 2023

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the accounts are laid out below.

Basis of preparation

These accounts have been prepared for the year to 31 December 2023.

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant accounting policies below or the notes to these accounts.

The accounts have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) (Charities SORP FRS 102) issued in October 2019, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The charity constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in sterling and are rounded to the nearest pound.

Critical accounting estimates and areas of judgement

Preparation of the accounts requires the trustees and management to make significant judgements and estimates.

The items in the accounts where judgements and estimates have been made include the judgement whether items meet the criteria for capitalisation as intangible fixed assets, estimating the amortisation and useful economic life and likely residual values, if any, of intangible and tangible fixed assets for the purposes of determining the annual depreciation charge.

Assessment of going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts. The trustees have made this assessment in respect to a period of one year from the date of approval of these accounts.

The trustees of the charity have concluded that the charity is able to continue as a going concern. The trustees are of the opinion that the charity will have sufficient resources to meet its liabilities as they fall due. The most significant areas of judgement that affect items in the accounts are detailed above. With regard to the next accounting period, the year ending 31 December 2024, the most significant areas that affect the carrying value of the assets held by the charity are the level of investment return and the performance of the investment markets.

Income recognition

Income is recognised in the period in which the charity becomes entitled to that income, where receipt of resources is probable and the amount can be measured reliably.

Income comprises subscriptions, income from scientific meetings and journals, investment income, donations and other income.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity. This is normally upon notification of the interest paid or payable by the bank.

Income is recognised in the statement of financial activities for the proportion of subscriptions, which are receivable in the financial period. Amounts received but not recognised in the statement of financial activities are carried forward in the balance sheet as deferred income.

Income from scientific meetings and journals is recognised in the statement of financial activities when the service is delivered. Amounts received but not recognised are carried forward in the balance sheet as deferred income.

Resources expended

All expenditure is accounted for on an accruals basis. Expenditure comprises direct costs and support costs. All expenses, including support costs, are allocated or apportioned to the applicable expenditure headings. The classification between activities is as follows:

- ◆ Expenditure on raising funds includes all expenditure associated with raising funds for the charity. This includes investment management fees.
- ◆ Expenditure on charitable activities includes all costs associated with furthering the charitable purposes of the charity through the provision of its charitable activities. Such costs include charitable grants and donations, direct and support costs in respect of the dissemination of information including governance costs.

Grants payable are included in the statement of financial activities when approved and when the intended recipient has either received the funds or been informed of the decision to make the grant and has satisfied all performance conditions. Grants approved but not paid at the end of the financial year are accrued. Grants where the beneficiary has not been informed or has to fulfil performance conditions before the grant is released are not accrued for but are disclosed as financial commitments in the notes to the accounts. Grants comprise single year payments rather than multi-year grants.

All expenditure is stated inclusive of irrecoverable VAT.

Allocation of support and governance costs

Support costs represent indirect charitable expenditure. In order to carry out the primary purposes of the charity it is necessary to provide support in the form of personnel development, financial procedures, provision of office services and equipment and a suitable working environment.

Governance costs comprise the costs involving the public accountability of the charity (including audit costs) and costs in respect of its compliance with regulation and good practice.

Support costs and governance costs are allocated in full to the charitable activity of dissemination of information.

Intangible fixed assets

All intangible assets purchased that have a cost of more than £500 and an expected useful economic life that exceeds one year are capitalised and classified as intangible fixed assets. Intangible fixed assets are stated at historical cost less amortisation. Amortisation is provided on all intangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

- ◆ CRM database – over 5 years.
- ◆ Contract relationship management software – 5 years

An annual impairment review is carried out for each asset after it has been brought into use to reassess its remaining useful life and that it still meets the definition of an intangible asset. Provision is made for assets that are no longer deemed to give an ongoing benefit to the charity for a period of greater than 12 months.

Tangible fixed assets

All tangible assets purchased that have a cost of more than £500 and an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

- ◆ Improvements to leasehold premises – over the life of the lease
- ◆ Fixtures and fittings – over 5 years
- ◆ Office equipment – over 5 years

Fixed asset investments

Listed investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

Fixed asset investments (continued)

The charity does not acquire put options, derivatives or other complex financial instruments.

Realised gains (or losses) on investment assets are calculated as the difference between disposal proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value at that date. Realised and unrealised investment gains (or losses) are combined in the statement of financial activities and are credited (or debited) in the year in which they arise.

Stocks

Stocks are valued at the lower cost or net realisable value.

Debtors

Debtors are recognised at their settlement amount, less any provision for non-recoverability. Prepayments are valued at the amount prepaid. They have been discounted to the present value of the future cash receipt where such discounting is material.

Cash at bank and in hand

Cash at bank and in hand represents such accounts and instruments that are available on demand or have a maturity of less than three months from the date of acquisition.

Creditors and provisions

Creditors and provisions are recognised when there is a legal or constructive obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Creditors and provisions are recognised at the amount the charity anticipates it will pay to settle the debt. They have been discounted to the present value of the future cash payment where such discounting is material.

Leased assets

Rentals applicable to operating leases where substantially all of the benefits and risks of ownership remain with the lessor are charged on a straight line basis over the term of the lease.

Pension contributions

The charity participates in a multi-employer defined benefit pension scheme known as the Superannuation Arrangements of the University of London ("SAUL"). The scheme is contracted out of the State Earnings-Related Pension Scheme and is a centralised scheme for certain employees with the assets held in separate trustee-administered funds. The charity is unable to identify its share of the underlying assets and liabilities of the scheme, therefore the financial statements include pension costs payable in respect of the plan on a defined contribution basis.

Fund accounting

The general fund comprises the accumulated surpluses of unrestricted incoming resources not yet expended, which are available for use in furtherance of the general objectives of the charity.

Designated funds are set aside out of unrestricted funds and consist of amounts which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year end are carried forward in the balance sheet.

1 Investment income

	Unrestricted funds £	Restricted funds £	2023 £
Bank interest receivable on short term cash deposits	16,624	—	16,624
Income from investments listed on a recognised stock exchange	64,484	—	64,484
2023 Total funds	81,108	—	81,108
	<i>Unrestricted funds £</i>	<i>Restricted funds £</i>	<i>2022 £</i>
<i>Bank interest receivable on short term cash deposits</i>	<i>3,065</i>	<i>—</i>	<i>3,065</i>
<i>Income from investments listed on a recognised stock exchange</i>	<i>64,484</i>	<i>—</i>	<i>64,484</i>
2022 Total funds	67,549	—	67,549

2 Income from dissemination of information

	Unrestricted funds £	Restricted funds £	2023 £
Subscriptions	580,418	—	580,418
Annual Scientific Meeting	909,802	—	909,802
Journal of Clinical Urology	85,231	—	85,231
Office of Education	178,649	—	178,649
Section of Oncology	105,376	—	105,376
Section of Endourology	177,332	—	177,332
Section of Female Urology	19,075	—	19,075
Section of Trainees	1,500	—	1,500
Industry sponsored webinars	35,683	—	35,683
Urolink	2,450	20	2,470
Data and audit	1,000	—	1,000
Other income	8,662	374	9,036
2023 Total funds	2,105,268	394	2,105,662
	<i>Unrestricted funds £</i>	<i>Restricted funds £</i>	<i>2022 £</i>
<i>Subscriptions</i>	<i>565,185</i>	<i>—</i>	<i>565,185</i>
<i>Annual Scientific Meeting</i>	<i>709,945</i>	<i>—</i>	<i>709,945</i>
<i>Other meetings</i>	<i>52,778</i>	<i>—</i>	<i>52,778</i>
<i>Journal of Clinical Urology</i>	<i>85,051</i>	<i>—</i>	<i>85,051</i>
<i>Office of Education</i>	<i>152,138</i>	<i>—</i>	<i>152,138</i>
<i>Section of Oncology</i>	<i>98,290</i>	<i>—</i>	<i>98,290</i>
<i>Section of Endourology</i>	<i>82,210</i>	<i>—</i>	<i>82,210</i>
<i>Section of Trainees</i>	<i>25,544</i>	<i>—</i>	<i>25,544</i>
<i>UK Fellowship Meeting</i>	<i>4,167</i>	<i>—</i>	<i>4,167</i>
<i>Industry sponsored webinars</i>	<i>9,733</i>	<i>—</i>	<i>9,733</i>
<i>Urolink</i>	<i>1,500</i>	<i>7,000</i>	<i>8,500</i>
<i>Other income</i>	<i>3,058</i>	<i>—</i>	<i>3,058</i>
2022 Total funds	1,789,599	7,000	1,796,599

3 Costs of dissemination of information (continued)

	Unrestricted funds £	Restricted funds £	2023 £
Direct costs:			
Annual Scientific Meeting	672,214	—	672,214
Journal of Clinical Urology	102,361	—	102,361
Office of Education	146,402	—	146,402
Section of Oncology	71,452	—	71,452
Section of Endourology	133,833	—	133,833
Section of Female Urology	12,785	—	12,785
Section of Trainees	29,482	—	29,482
Section of Andrology	3,066	—	3,066
Section of Academic Urology	3,000	—	3,000
Industry sponsored webinars	2,100	—	2,100
Data and audit	1,395	—	1,395
British Journal of Urology International	66,500	—	66,500
Grants, donations and awards (see note 4)	2,729	374	3,103
Urolink	14,796	6,363	21,159
Subscriptions	8,899	—	8,899
Website Costs	10,151	—	10,151
	1,281,165	6,737	1,287,902
Support costs (see note 5)	623,766	—	623,766
Governance costs (see note 5)	64,236	—	64,236
2023 Total funds	1,969,167	6,737	1,975,904
	Unrestricted funds £	Restricted funds £	2022 £
Direct costs:			
Annual Scientific Meeting	572,227	—	572,227
Other meetings	30,425	—	30,425
Journal of Clinical Urology	80,694	—	80,694
Office of Education	103,552	—	103,552
Section of Oncology	71,433	—	71,433
Section of Endourology	47,531	—	47,531
Section of Female Urology	1,006	—	1,006
Section of Trainees	27,344	—	27,344
Section of Andrology	2,130	—	2,130
Section of Academic Urology	3,000	—	3,000
Industry sponsored webinars	500	—	500
Data and audit	7,077	—	7,077
British Journal of Urology International	66,507	—	66,507
Grants, donations and awards (see note 4)	1,483	—	1,483
Urolink	18,515	19,036	37,551
Subscriptions	4,386	—	4,386
Website Costs	6,075	—	6,075
	1,043,885	19,036	1,062,921
Support costs (see note 5)	682,088	—	682,088
Governance costs (see note 5)	103,503	—	103,503
2022 Total funds	1,829,476	19,036	1,848,512

4 Prizes, donations and awards

	Unrestricted funds £	Restricted funds £	2023 £
Other Grants	1,750	374	2,124
Medals awarded to five individuals	979	—	979
2023 Total funds	2,729	374	3,103
	<i>Unrestricted funds £</i>	<i>Restricted funds £</i>	<i>2022 £</i>
<i>Other Grants</i>	<i>122</i>	<i>—</i>	<i>122</i>
<i>Medals awarded to five individuals</i>	<i>1,361</i>	<i>—</i>	<i>1,361</i>
2022 Total funds	1,483	—	1,483

5 Support and governance costs

	Support costs £	Governance £	2023 £
Staff costs (see note 7)	424,136	—	424,136
Staff recruitment, training, travel and welfare	5,747	—	5,747
Council and committee expenses	—	8,934	8,934
President's expenses and Officer's sessional time	—	45,752	45,752
Accommodation costs	48,150	—	48,150
Repairs, maintenance, and computer software expenses	68,726	—	68,726
Postage, mailings, printing and stationery	6,370	—	6,370
Legal and professional fees	53,591	—	53,591
Auditors' remuneration:			
. Audit – current year	—	9,550	9,550
. Accountancy and advisory	8,250	—	8,250
Bank and credit card charges	30,678	—	30,678
Bad debt write off	6,576	—	6,576
Irrecoverable VAT	(33,123)	—	(33,123)
Sundry office expenses	1,043	—	1,043
Depreciation	3,622	—	3,622
	623,766	64,236	688,002

5 Support and governance costs (continued)

	Support costs £	Governance £	2022 £
Staff costs (see note 7)	452,242	—	452,242
Staff recruitment, training, travel and welfare	2,674	—	2,674
Council and committee expenses	—	37,471	37,471
President's expenses and Officer's sessional time	—	44,982	44,982
Accommodation costs	48,754	—	48,754
Repairs, maintenance, and computer software expenses	42,865	—	42,865
Telephone	1,071	—	1,071
Postage, mailings, printing and stationery	4,940	—	4,940
Legal and professional fees	65,823	—	65,823
Auditors' remuneration:			
. Audit – current year	—	8,250	8,250
. Accountancy and advisory	—	12,800	12,800
Bank and credit card charges	22,875	—	22,875
Irrecoverable VAT	5,190	—	5,190
Irrecoverable future AGM deposit funds	16,786	—	16,786
Sundry office expenses	5,782	—	5,782
Depreciation	3,726	—	3,726
Amortisation	9,360	—	9,360
	682,088	103,503	785,591

6 Net income (expenditure) before gains on investments

This is stated after charging:

	2023 £	2022 £
Staff costs (see note 7)	424,136	452,242
Depreciation	3,622	3,726
Amortisation	—	9,360
Operating lease charges	41,408	48,601
Auditors' remuneration		
. Audit – current year	9,550	8,250
. Other services – current year	—	3,900

7 Staff costs and remuneration of key management personnel

The average number of persons employed by the charity (excluding council members), during the year was as follows:

	2023 No.	2022 No.
Office and administration	8	9

4 full-time and 4 part-time (2022 – 6 full-time, 3 part-time).

Staff costs for the above persons:

	2023 £	2022 £
Wages and salaries	331,218	360,574
Social security costs	29,014	35,488
Other pension costs	63,904	56,180
	424,136	452,242

7 Staff costs and remuneration of key management personnel (continued)

No trustee received any remuneration for services to the charity as a member of Council during the current or previous year. During the year, seven (2022 – eight) trustees were reimbursed for travel and meetings expenses totalling £14,468 (2022 – £10,155). BAUS reimbursed the employing trust of the BAUS President for two sessions per week and the employing trust of the Vice President for one session per week, amounting to £35,935 (2022 – £30,997).

During the year the number of employees earning £60,000 or more (including taxable benefits but excluding employer pension contributions) was as follows:

	2023 No.	2022 No.
£80,001 - £90,000	1	1

The pension contributions payable for these employees amounted to £18,153 (2022 – £14,960).

The key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis comprise the trustees, the Chief Executive and Deputy Chief Executive. The total employment costs (including employer's national insurance and pension contributions) of the key management personnel for the year was £193,027 (2022 – £184,596).

8 Taxation

The charity is not liable to corporation tax on income derived from its charitable activities, as it falls within the various exemptions available to registered charities.

9 Intangible fixed assets

	Asset under development £	CRM database £
Cost		
At 1 January 2023	—	46,800
Additions	38,400	—
At 31 December 2023	38,400	46,800
Amortisation		
At 1 January 2023	—	46,800
Charge for the year	—	—
At 31 December 2023	—	46,800
Net book values		
At 31 December 2023	38,400	—
At 31 December 2022	—	—

10 Tangible fixed assets

	Fixtures & fittings £	Computer equipment £	Total £
Cost			
At 1 January 2023	5,496	19,583	25,079
Additions	—	1,662	1,662
At 31 December 2023	<u>5,496</u>	<u>21,245</u>	<u>26,741</u>
Depreciation			
At 1 January 2023	4,896	10,979	15,875
Charge for the year	—	3,622	3,622
At 31 December 2023	<u>4,896</u>	<u>14,601</u>	<u>19,497</u>
Net book values			
At 31 December 2023	<u>600</u>	<u>6,644</u>	<u>7,244</u>
At 31 December 2022	<u>600</u>	<u>8,604</u>	<u>9,204</u>

11 Investments

	2023 £	2022 £
Investments listed on a recognised stock exchange at market value		
1 January 2023	2,151,228	2,434,292
Unrealised gains (losses)	197,678	(283,064)
At 31 December 2023	<u>2,348,906</u>	<u>2,151,228</u>

At the balance sheet date, the historical cost of the investments was £1,972,364 (2022 – £1,972,364).

At the balance sheet date, the investment portfolio comprised wholly of the COIF Charities investment fund and comprised the following:

	2023 £	2022 £
Global equities	1,522,795	1,273,527
Other assets	214,455	322,039
UK equities	151,270	198,128
Infrastructure and operating assets	151,974	181,133
Fixed interest	206,704	106,486
Property	101,708	69,915
	<u>2,348,906</u>	<u>2,151,228</u>

12 Debtors

	2023 £	2022 £
Amounts falling due within one year:		
Trade debtors	538,790	455,139
Prepayments	231,595	243,513
Accrued income	78,853	76,913
Other debtors	15	—
	849,253	775,565
Amounts falling due after more than one year:		
Prepayments	21,491	21,117
	870,744	796,682

13 Creditors: amounts falling due within one year

	2023 £	2022 £
Amounts falling due within one year:		
Trade creditors	99,748	57,786
Other taxes and social security costs	—	13,516
VAT payable	71,553	53,811
Accruals	55,306	35,532
Deferred income:		
. Annual meeting income received in advance	516,410	410,010
. Office of Education income received in advance	29,754	37,033
. BSoT income received in advance	7,896	—
. Industry sponsorship webinars/meetings	25,500	17,100
. Subscription income received in advance	136	330
	806,303	625,118

Income has been deferred because the charity has not yet met the conditions for recognising the income. The movements on deferred income are analysed below:

	2023 £	2022 £
Brought forward	464,473	326,712
Released in year	(464,473)	(326,712)
Additions in year	554,196	464,473
Carried forward	554,196	464,473

14 Funds

	1 January 2023 £	Income £	Expenditure £	Gains on investments £	31 December 2023 £
Restricted income funds:					
. UROLINK fund	30,485	20	(6,363)	—	24,142
. Other	—	374	(374)	—	—
Designated funds:					
. Section of Trainees fund	57,053	1,500	(26,497)	6,371	38,427
. Endourology fund	315,031	—	(3,191)	33,956	345,796
Unrestricted income funds:					
. General fund	2,783,171	2,184,876	(1,939,479)	157,351	3,185,919
	3,185,740	2,186,770	(1,975,904)	197,678	3,594,284

14 Funds (continued)

	1 January 2022 £	Income £	Expenditure £	Gains on investments £	31 December 2022 £
<i>Restricted income funds:</i>					
. UROLINK fund	42,521	7,000	(19,036)	—	30,485
<i>Designated funds:</i>					
. Section of Trainees fund	63,858	25,544	(25,857)	(6,492)	57,053
. Endourology fund	351,487	—	1,000	(37,456)	315,031
<i>Unrestricted income funds:</i>					
. General fund	2,995,302	1,831,604	(1,804,619)	(239,116)	2,783,171
	<u>3,453,168</u>	<u>1,864,148</u>	<u>(1,848,512)</u>	<u>(283,064)</u>	<u>3,185,740</u>

The UROLINK Fund was set up in 2008 by the unincorporated Association with a donation received from BJU international. Further funds have been received in recent years from BJU International and The Urology Foundation. These monies continue to be utilised to support UROLINK activities.

The Endourology designated fund represents the net surplus generated from the World Congress of Endourology, which will be used to support fellowships in endourology. It is anticipated this fund will be spent over a maximum of ten years.

The BAUS Section of Trainees (BSoT) designated fund represents the monies transferred to BAUS in 2019 when the Specialist Urology Registrars' Group (SURG), which had been a separate charity, ceased to exist and the BSoT was formed as part of BAUS. Trustees agreed these funds plus any surpluses generated by BSoT activities could be held in a designated fund to support urological training/trainees.

15 Analysis of net assets between funds

	Fixed assets £	Investments £	Net current assets £	2023 Total £
<i>Restricted income funds:</i>				
. UROLINK fund	—	—	24,142	24,142
<i>Designated income funds</i>	—	345,796	—	345,796
<i>Unrestricted income funds</i>				
. General fund	45,644	2,003,110	1,175,592	3,224,346
	<u>45,644</u>	<u>2,348,906</u>	<u>1,199,734</u>	<u>3,594,284</u>

	Fixed assets £	Investments £	Net current assets £	2022 Total £
<i>Restricted income funds:</i>				
. UROLINK fund	—	—	30,485	30,485
<i>Designated income funds</i>	—	372,084	—	372,084
<i>Unrestricted income funds</i>				
. General fund	9,204	1,779,144	994,823	2,783,171
	<u>9,204</u>	<u>2,151,228</u>	<u>1,025,308</u>	<u>3,185,740</u>

15 Analysis of net assets between funds (continued)

The total unrealised gains as at 31 December 2023 constitutes movements on fair value and are as follows:

	2023 £	2022 £
Unrealised gains included above:		
On investments	376,542	178,864
Total unrealised gains at 31 December 2023	376,542	178,864
Reconciliation of movements in unrealised gains		
Unrealised gains at 1 January 2023	178,864	461,928
Add: net (losses) gains arising on fair value movements arising in the year	197,678	(283,064)
Total unrealised gains at 31 December 2023	376,542	178,864

16 Commitments under operating leases

At 31 December 2023, the charitable company had the following future minimum commitments under non-cancellable operating leases as follows:

	2023 £	2022 £
In respect of land and building leases		
Payments which fall due:		
. Within one year	43,080	43,080
. Within two to five years	57,296	100,376
	100,376	143,456

17 Pension commitments

The charitable company participates in pension schemes provided by the Superannuation Arrangements for the University of London (SAUL) for all qualified employees. SAUL provides pension benefits for eligible employees of multiple, separate employers. SAUL offers two types of pension as set out in the Scheme Rules:

- a defined benefit (DB) plan that pays members' benefits according to a set formula, based on members' salaries
- a defined contribution (DC) plan for the first three years of membership, called SAUL Start, that gives members an individual pension pot which is invested for their retirement.

Generally, members who joined or became eligible for SAUL before 1 April 2023 will be in the DB plan. Members who become eligible for the first time from 1 April 2023 will be in SAUL Start for their first three years of membership before automatically moving to the DB plan. The DB scheme has assets held in trustee administered funds and it is not possible to identify the charitable company's share of the underlying assets and liabilities of SAUL. Therefore contributions are accounted for as if SAUL were a defined contribution scheme and pension costs are based on the amounts actually payable (cash amounts) in accordance with FRS 102. The amount charged to the Statement of Financial Activities in respect of pension costs (as shown in note 7) is the total contributions payable for the year. Any contributions payable at the balance sheet date are treated as creditors (as shown in note 13).

17 Pension commitments (continued)

Pre-retirement discount rate	4.06% per annum
Post-retirement discount rate	1.96% per annum
General salary increases	3.49% per annum
Price inflation – RPI	3.39% per annum
Price inflation – CPI	2.49% per annum
Pension increases in payment	2.49% per annum

The actuarial valuation applies to SAUL as a whole and does not identify surpluses or deficits applicable to individual employers. The 2023 valuation will be formally agreed by SAUL in May 2024. The preliminary assessment for the outcome of the 2023 valuation of the DB scheme shows the scheme is fully funded with a surplus of £134 million.

18 Related party transactions

There were no transactions with a related party requiring disclosure during the period (2022 – £nil, see note 7 to the financial statements).